Regulus Therapeutics has named William Rastetter as a member of its board.
Rastetter previously served as CEO of Idec Pharmaceuticals, and served as executive chairman of BiogenIdec following the merger of Idec and Biogen.
He holds a BS in chemistry from the Massachusetts Institute of Technology and an MA and PhD in chemistry from Harvard University.
The American Association for Cancer Research has unveiled its first class of fellow of the AACR Academy including three researchers with backgrounds in RNAi and microRNAs.
Included in the class is Carlo Croce, professor and chair of molecular virology, immunology, and medical genetics at the Ohio State University School of Medicine. Croce has conducted key research into the role of miRNAs in cancer.
Also elected is Tyler Jacks, professor of biology at the Massachusetts Institute of Technology and Howard Hughes Medical Institute investigator. His research includes the examination of miRNA expression in tumors.
Also named as a fellow is Phillip Sharp, an institute professor at MIT and Nobel Laureate. Sharp’s lab conducts key research on RNAi and miRNAs, and Sharp is a co-founder of RNAi therapeutics firm Alnylam Pharmaceuticals.